EUVIMEDEUVIMED entdecken
Crossref

DMF-DMA catalyzed Synthesis, molecular docking, in-vitro, in-silico design, and binding free energy studies of novel thiohydantoin derivatives as antioxidant and antiproliferative agents targeting EGFR tyrosine kinase and aromatase cytochrome P450 enzyme

Israa A Seliem

Bioorganic Chemistry · 2024

DOI: 10.1016/j.bioorg.2024.107601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Israa A Seliem. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44511, Egypt. Electronic address: iasliem@pharmacy.z…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cell Proliferation, Molecular Docking Simulation, Antioxidants. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A set of novels 2-thiohydantoin derivatives were synthesized and enaminone function was discussed at position 5 using DMFDMA catalyst which result in formation of pyrazole, isoxazole, benzoxazepine by using reagents such as hydrazine, hydroxylamine and 2-aminothiophenol. These newly synthesized compounds were evaluated for their antioxidant and antiproliferative activity. In vitro studies on the effect of 2-thiohydantoin on scavenging 2,2-diphenyl-1-picrylhydrazyl radical (DPPH•) confirmed the free radical scavenging and antioxidant activity of 2-thiohydantoin. The synthesized compounds show significant antioxidant activity. The in vitro antitumor activity of 2-thiohydantoin on MCF7 (breast) and PC3 cells (prostate) was evaluated using MTT assay. Some of the synthesized compounds show significant to moderate antiproliferative properties compared to reference drug erlotinib. Among all, compound 4a exhibit potent antitumor properties against MCF7 and PC3 cancer cell lines with IC50 = 2.53 ± 0.09 /ml & with IC50 = 3.25 ± 0.12 µg/ml respectively and has potent antioxidant activity with IC50 = 10.04 ± 0.49 µg/ml.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCell ProliferationMolecular Docking SimulationAntioxidantsErbB ReceptorsDrug Screening Assays, AntitumorThiohydantoinsAromataseHumansStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugDrug DesignProtein Kinase InhibitorsCatalysisBiphenyl CompoundsCell Line, TumorThermodynamicsPicratesHydrazinesThioamides

Stichwörter der Autor:innen

AntioxidantAntiproliferativeDMFDMADPPHFree radicalPyrazoleThiohydantoin

Substanzen

Antineoplastic AgentsAntioxidantsErbB ReceptorsThiohydantoinsAromataseEGFR protein, humanProtein Kinase InhibitorshydrazinecarbothioamideBiphenyl CompoundsPicrates

Autor:innen und Institutionen

  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44511, Egypt. Electronic address: iasliem@pharmacy.zu.edu.eg.

Zitieren

APA

Seliem, I. A. (2024). DMF-DMA catalyzed Synthesis, molecular docking, in-vitro, in-silico design, and binding free energy studies of novel thiohydantoin derivatives as antioxidant and antiproliferative agents targeting EGFR tyrosine kinase and aromatase cytochrome P450 enzyme. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107601

Vancouver

Seliem IA. DMF-DMA catalyzed Synthesis, molecular docking, in-vitro, in-silico design, and binding free energy studies of novel thiohydantoin derivatives as antioxidant and antiproliferative agents targeting EGFR tyrosine kinase and aromatase cytochrome P450 enzyme. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107601

BibTeX
@article{Seliem2024,
  author = {Seliem, Israa A},
  title = {DMF-DMA catalyzed Synthesis, molecular docking, in-vitro, in-silico design, and binding free energy studies of novel thiohydantoin derivatives as antioxidant and antiproliferative agents targeting EGFR tyrosine kinase and aromatase cytochrome P450 enzyme},
  journal = {Bioorganic Chemistry},
  year = {2024},
  doi = {10.1016/j.bioorg.2024.107601}
}
Kostenlos starten →